Cerulea Clinical Trials has announced the appointment of senior pharmaceutical and biotechnology executive Dr Michelle Bradney as its new Chief Executive Officer, effective 20 October 2025.
Dr Bradney brings more than two decades of experience in medical affairs and clinical development across global pharmaceutical companies and ASX-listed biotechnology firms. She joins Cerulea from OccuRx, where she served as Chief Operating Officer, and has held senior roles at Allergan, leading ophthalmic clinical monitoring operations.
In addition to her executive experience, Dr Bradney holds governance roles across the life sciences sector, including serving as a board observer with Medicines Australia and a member of the Women on Boards Naomi Simson syndicate.
Cerulea Chair Professor Keith Martin welcomed the appointment, describing Dr Bradney’s leadership as pivotal to the company’s next phase of growth.
“Michelle Bradney brings a wealth of experience in navigating complex regulatory environments and managing high-stakes clinical trial operations,” Professor Martin said. “I look forward to working with her to expand the number of trials delivered, attract new industry-sponsored ophthalmic studies to Australia, and establish Cerulea as a global hub for ophthalmic clinical trials.”
Dr Bradney said she was eager to build on Cerulea’s strong foundation and strengthen its role in advancing eye-health innovation.
“I’m thrilled to join Cerulea and build on the success of its clinical trial unit,” she said. “Our goal is to attract new trials locally and internationally, giving people living with eye disease access to cutting-edge treatments and improving outcomes.”
Dr Bradney succeeds Dr Adele Hosseini, who has served as Interim CEO since May 2025.
“I thank Adele for her outstanding leadership as interim CEO, which has laid a strong foundation for the future growth and success of Cerulea,” Professor Martin said.
Cerulea Clinical Trials specialises in the delivery of ophthalmic clinical trials, partnering with industry and academic researchers to accelerate access to new therapies for patients with vision-impairing conditions.